Last reviewed · How we verify

NCT05514353

A Phase 1 Study to Assess Single and Multiple Ascending Doses of PBI-100 Topical Cream

Completed Phase 1 Last updated 29 March 2023
What this trial tests

Phase 1 trial testing PBI-100 Topical Cream in Healthy Volunteers in 32 participants. Completed in 12 January 2023.

Timeline
28 December 2021
Primary endpoint
12 January 2023
12 January 2023

Quick facts

Lead sponsorPyramid Biosciences
PhasePhase 1
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designsequential
Maskingdouble
Primary purposetreatment
Enrollment32
Start date28 December 2021
Primary completion12 January 2023
Estimated completion12 January 2023
Sites1 location across United States

Drugs / interventions tested

Conditions studied

Sponsor

Pyramid Biosciences — full company profile →

Who can join

Adults 18 to 65, any sex, with Healthy Volunteers or Psoriasis. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This is a Phase 1, randomized, double-blind, vehicle-controlled, SAD / MAD study evaluating three dose levels of PBI-100 topical cream in healthy adult volunteers and/or subjects with psoriasis.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of PBI-100 Topical Cream

Trials testing the same drug.

Other recruiting trials for Healthy Volunteers

Currently open trials in the same condition.

Other Pyramid Biosciences trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05514353.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing